{| class = "wikitable" style = "float:right; font-size:85%; margin-left:15px"
|+ <br />单克隆抗体命名法词根列表<ref name="AMA_2007" /><ref name="WHO_2009" /><ref name="StemBook_2009" /><ref>{{cite web | title=Monoclonal Antibodies | website=American Medical Association | date=2016-05-04 | url=https://www.ama-assn.org/about/united-states-adopted-names/monoclonal-antibodies | access-date=2020-08-07 | archive-date=2022-02-23 | archive-url=https://web.archive.org/web/20220223084722/https://www.ama-assn.org/about/united-states-adopted-names/monoclonal-antibodies }}</ref><ref name="WHO 2017 Revised nomenclature" /><ref>{{cite report | url=https://www.who.int/medicines/services/inn/BioReview2019.pdf | title=International Nonproprietary Names (INN) for biological and biotechnological substances (a review) | id=WHO/EMP/RHT/TSN/2019.1 | year=2019 | date= | access-date=2020-12-06 | archive-date=2022-01-19 | archive-url=https://web.archive.org/web/20220119103511/http://www.who.int/medicines/services/inn/BioReview2019.pdf }}</ref>
|-
! 前缀
! colspan = "4" | 靶点亚词干
! colspan="2" | 来源亚词干（至2017前）
! 词干
|-
! || 旧系统<br />（~1993） || （2009） || 新系统<br />（2017） || 意义 || || 意义 ||
|-
| rowspan="23" | 可变
| — || ''-ami-'' ||  ''-ami-'' || {{link-en|血清淀粉样蛋白P组分|Serum amyloid P component|血清淀粉样蛋白<br />(SAP)/淀粉样变}}（用于亚词干之前）
| ''-a-'' || [[大鼠|大鼠]]
| rowspan="23" | ''-mab''
|-
| ''-anibi-'' || — || — || [[血管新生|血管新生]] (抑制剂)
| ''-e-'' || [[仓鼠|仓鼠]]
|-
| ''-ba(c)-'' || ''-b(a)-'' || ''-ba-'' || [[细菌|细菌]]
| ''-i-'' || [[灵长类|灵长类]]
|-
| ''-ci(r)-'' || ''-c(i)-'' || ''-ci-'' || [[循环系统|心血管]]
| ''-o-'' || [[小鼠|小鼠]]
|-
| ''-fung-'' || ''-f(u)-'' || ''-fung-'' || [[真菌|真菌]]
| ''-u-'' || [[人类|人类]]
|-
| ''-d(e)-'' || ''-de-'' || — || [[内分泌系统|内分泌]]
| ''-xi-'' || {{link-en|Fusion protein|融合蛋白|嵌合抗体}}（人类/异源抗体）
|-
| ''-gr(o)-'' || ''-gros-'' || ''-gros-'' || [[生长因子|骨骼肌质量相关生长因子]]<br />及受体（用于亚词干之前）
| ''-zu-'' || {{link-en|Humanized antibody|人源化抗体|人源化}}
|-
| ''-ki(n)-'' || ''-k(i)-'' || ''-ki-'' || [[白细胞介素|白细胞介素]]
| ''-xizu-'' || 嵌合-人源化杂合
|-
| ''-les-'' || — || — || 炎症{{link-en|病灶|lesion}}{{fact|date=August 2020}}
| rowspan="2" | ''-axo-'' || rowspan="2" | 大鼠-小鼠杂合<br />(见{{link-en|三功能抗体|trifunctional antibody}}'')
|-
| ''-li(m)-'' || ''-l(i)-'' || ''-li-'' || [[免疫系统|免疫调节]]
|-
| ''-mul-'' || — || — || [[肌肉骨骼系统|肌肉骨骼系统]]{{fact|date=August 2020}} || rowspan="13" colspan = "2" | 
|-
| ''-ne(u)(r)-'' || ''-n(e)-''* || ''-ne-'' || [[神经系统|神经]]
|-
| ''-os-'' || ''-s(o)-'' || ''-os-'' || [[骨骼|骨骼]]
|-
| ''-co(l)-'' || rowspan="7" | ''-t(u)-'' || rowspan="7" | ''-ta-'' || [[结直肠癌|大肠肿瘤]]
|-
| ''-go(t)-'' || [[睾丸癌|睾丸肿瘤]]
|-
| ''-go(v)-''  || [[卵巢癌|卵巢肿瘤]]
|-
| ''-ma(r)-''  || [[乳腺癌|乳腺肿瘤]]
|-
| ''-me(l)-''  || [[黑色素瘤|黑色素瘤]]
|-
| ''-pr(o)-''  || [[前列腺癌|前列腺肿瘤]]
|-
| ''-tu(m)-''  || 杂类肿瘤
|-
|''-toxa-'' || ''-tox(a)-'' || ''-toxa-'' || [[毒素|毒素]]
|-
| — || — || ''-vet-'' || [[兽医学|兽用]]（用于词干之前）
|-
| ''-vi(r)-'' || ''-v(i)-'' || ''-vi-'' || [[病毒|病毒]]
|-
|}

'''单克隆抗体命名法'''适用于[[单克隆抗体|单克隆抗体]]的学名或非专利药名。[[抗体|抗体]]是[[B细胞|B细胞]]产生的一种蛋白。人及其他[[脊椎动物|脊椎动物]]的免疫系统通过抗体识别[[细菌|细菌]]、[[病毒|病毒]]等外源物质。单克隆抗体（单抗）由{{link-en|克隆 (细胞生物学)|Clone (cell biology)|相同细胞}}产生，因此拥有相同靶点；产生单抗的细胞细胞通常由人工产生。单抗在医学和其他领域应用众多。<ref name="Janeway" />

[[世界卫生组织|世界卫生组织]][[国际非专利药品名称|国际非专利药品名称]]（INN）<ref name="WHO_1997" />及{{link-en|美国采用名|United States Adopted Name
}}（USAN）<ref name="AMA_2007" />皆使用此命名系统。[[词根|词根]]一般用于表示药品类别，大多数情况下置于词尾。单抗名称均以“-mab”结尾。与大多数其他药品不同，单抗命名根据结构及功能在词尾前添加不同[[语素|语素]]<ref name="AMA_2007" /><ref>{{Cite journal|title=Nomenclature of humanized mAbs: Early concepts, current challenges and future perspectives|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6294595/|last=Mayrhofer|first=Patrick|last2=Kunert|first2=Renate|journal=Human Antibodies|issue=1|doi=10.3233/HAB-180347|volume=27|pages=37–51|issn=1093-2607|pmc=6294595|pmid=30103312|access-date=2020-12-07|archive-date=2021-03-09|archive-url=https://web.archive.org/web/20210309005454/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6294595/}}</ref>。<!-- 此类语素的正式名称为“亚词根”；亚词根有时被错误称为“中缀”（包括USAN委员会）。-->

==组成部分==
[[File:Antibody_IgG2.png|thumb]]）。图中左上及右上方最外结构是四个[[可变区|可变区]]。]]

=== 词干 ===

“-mab”词干用于单克隆抗体及包含至少一个[[可变区|可变区]]（用于结合靶点的[[蛋白结构域|蛋白结构域]]）的片段。<ref name="WHO-INN" />{{link-en|抗原结合片段|Fragment antigen-binding}}<ref name="Ranibizumab" />、{{link-en|单链可变片段|single-chain variable fragment}}<ref name="Pexelizumab" />等人工合成蛋白因此适用本命名法。抗体的其他片段（如{{link-en|可结晶区域片段|Fragment crystallizable region}}）及[[拟抗体|拟抗体]]适用其他命名系统。

=== 来源亚词干 ===
[[File:Chimeric_and_humanized_antibodies_with_CDRs.svg|thumb]]以三个环表示。]]

在2017年初以前命名的抗体中词干前的亚词干用于表示产生该抗体的动物。<ref name="AMA_2007" />单抗首先于[[小鼠|小鼠]]（亚词干“-o-”与“-mab”结合为词尾“-omab”）及其他非人动物中产生。INN与USAN在该系统废止前未接到命名[[大鼠|大鼠]]（“-a-”）、[[仓鼠|仓鼠]]（“-e-”）、[[灵长类|灵长类]]（“-i-”）抗体的请求。<ref name="WHO-INN" />

人免疫系统会将非人抗体识别为异物，或将此类抗体从体内迅速{{link-en|清除 (药理学)|Clearance (pharmacology)|清除}}，或产生[[过敏反应|过敏反应]]。<ref name="Stern" /><ref name="Tabrizi" />为防止此类副作用，抗体中一些片段可由人类[[氨基酸序列|氨基酸序列]]替换，亦可{{link-en|蛋白质工程|protein engineering|设计制造}}完全人类抗体。{{link-en|Fusion protein|融合蛋白|嵌合抗体}}是[[恒定区|恒定区]]替换为人类恒定区的抗体，使用亚词干“-xi-”。{{link-en|人源化抗体|Humanized antibody}}是可变区一部分替换为人类可变区的抗体，使用亚词干“-zu-”；人源化抗体除负责识别靶点的[[互补性决定区|互补性决定区]]外所有片段一般皆由人类片段取代，有时会保留一些非人片段以保证具有良好结合能力。带有嵌合片段及人源化片段的抗体使用亚词干“-xizu-”。上述亚词干不表示用于生产抗体的物种。因此人-小鼠嵌合抗体{{link-en|巴利昔单抗|basiliximab}}（basiliximab）与人-[[猕猴|猕猴]]抗体{{link-en|戈利昔单抗|gomiliximab}}（gomiliximab）皆以“-ximab”结尾。纯人类抗体使用“-u-”。<ref name="WHO_2009" />

可将大鼠-小鼠杂合抗体设计为同时结合两种不同抗原。此类药物为{{link-en|三功能抗体|trifunctional antibody}}，使用亚词干“-axo-”。<ref name="Lordick" />

=== 靶点亚词干 ===

<!-- 单抗来源之前的亚词干表示其靶点。靶点包括[[肿瘤|肿瘤]]、[[器官系统|器官系统]]（如[[循环系统|循环系统]]）、[[病原体|病原体]]（[[细菌|细菌]]、[[病毒|病毒]]等）。靶点亚词干不表示抗体所施加作用。本命名法亦不区分[[治疗|治疗]]、[[预防医学|预防]]、[[诊断|诊断]]用剂。--><!--与USAN 2019 Naming Policy矛盾-->


命名方法推广之初靶点亚词干一般由一个辅音、一个元音、另一个辅音组成。最后的字母可在合成词难以发音时去除。循环系统使用“-ci(r)-”、免疫系统使用“-li(m)-”（lim来自[[淋巴细胞|淋巴细胞]]，lymphocyte）、神经系统使用“-ne(r)-”。靶点亚词干的最后一个字母通常在来源亚词干以辅音开始时（如“-zu-”、“-xi-”）省略，但也存在一些例外。由于目前仍不存在以[[肌肉骨骼系统|肌肉骨骼系统]]为靶点的嵌合或人源化抗体INN药名，“-mul-”词干从未缩略为“-mu-”。靶点与来源亚词干合并后可产生“-limumab”（免疫系统人类抗体）、“-ciximab”（循环系统嵌合抗体，省略辅音r）等词尾。<ref name="AMA_2007" />

2009年命名法起启用了更短的靶点亚词干。新亚词干由一个辅音、一个元音组成，元音可在来源亚词干以元音开始时省略。人类免疫系统抗体词干因此为“-lumab”而非旧词干“-limumab”。“-ciximab”在内的一些词尾未变化。<ref name="WHO_2009" />旧系统中依照肿瘤类型有七种肿瘤靶点亚词干。由于许多抗体在不同肿瘤中得到研究，新命名法仅使用“-t(u)-”表示肿瘤。<ref name="AMA_2007" />

=== 前缀 ===
前缀无特殊意义。前缀在每一药品中应独特，并构成优雅命名（“well-sounding name”）。<ref name="WHO_2009" />具有相同来源和靶位亚词干的抗体因此仅有前缀相区分。识别完全相同靶位的抗体前缀亦有所不同：[[阿达木单抗|阿达木单抗]]（''ada''limumab）与[[戈利木单抗|戈利木单抗]]（''go''limumab）皆为{{link-en|肿瘤坏死因子抑制剂|TNF inhibitor}}，其前缀因其化学结构而不同。<ref name="Adalimumab" /><ref name="Golimumab" />

=== 附加词 ===

抗体有时会以不同其他物质进行化学修饰，这些修饰在抗体名后以附加次体现。<ref name="WHO_2009" />其原因如下：
* 抗体可由{{link-en|聚乙二醇化|PEGylation}}（[[聚乙二醇|聚乙二醇]]修饰）延缓酶降解，防止降低[[免疫原性|免疫原性]]；<ref name="Veronese" />此修饰由“pegol”表示，如{{link-en|培阿赛珠单抗|alacizumab pegol}}（alacizumab pegol）。<ref name="Alacizumab" />
* 肿瘤抗体可以[[细胞毒素|细胞毒性分子]]修饰达到{{link-en|靶向给药|Targeted drug delivery}}。{{link-en|单甲基奥瑞他汀E|monomethyl auristatin E}}本身有毒，但在与抗体结合后可对癌细胞产生特异毒性，如{{link-en|格来莫单抗凡酯|glembatumumab vedotin}}（glembatumumab vedotin）；其附加词为“veotin”。<ref name="Glembatumumab" />
* 抗体可由[[螯合剂|螯合剂]]修饰以螯合[[放射性同位素|放射性同位素]]。{{link-en|三胺五乙酸|pentetic acid}}衍生物{{link-en|喷地肽|pendetide}}可与{{link-en|铟-111|indium-111}}螯合，如{{link-en|卡罗单抗喷地肽|capromab pendetide}}（capromab pendetide）。<ref name="Capromab" />如药品包含放射性同位素，同位素名应在抗体名之前。<ref name="WHO_2009" /> 卡罗单抗喷地肽的正式名称因此为“铟（<sup>111</sup>In）卡罗单抗喷地肽”。<ref name="Capromab" />

== 历史 ==
[[File:E_A_Behring.jpg|thumb]]，抗体的发现者之一]]
[[埃米尔·阿道夫·冯·贝林|埃米尔·阿道夫·冯·贝林]]与[[北里柴三郎|北里柴三郎]]在1890年发现血液中存在中和{{link-en|白喉毒素|diphtheria toxin}}与{{link-en|破伤风毒素|tetanospasmin}}的物质，并将其命名为抗毒素；他们还发现抗毒素对毒素有特异性。<ref name="Kitasato" />冯·贝林以此发现于1901年获得了第一枚[[诺贝尔生理学或医学奖|诺贝尔生理学或医学奖]]。<ref name="Nobel-1901" />此发现一年后[[保罗·埃尔利希|保罗·埃尔利希]]将抗毒素称为抗体（{{lang|ge|Antikörper}}）。<ref name="Lindenmann" />

[[乔治斯·克勒|乔治斯·克勒]]与[[色萨·米尔斯坦|色萨·米尔斯坦]]于1975年发明了{{link-en|杂交瘤技术|Hybridoma technology}}，奠定了生产单克隆抗体的基础；<ref name="Köhler" />克勒与米尔斯坦因此发现与[[尼尔斯·杰尼|尼尔斯·杰尼]]共同获得1984年诺贝尔生理学或医学奖。<ref name="Nobel-1984" />[[莫罗单抗-CD3|莫罗单抗-CD3]]于1986年获准成为第一个获准进行人类临床应用的单抗。<ref name="Mutschler" />

世界卫生组织（WHO）于1950年建立了国际非专利药品名称（INN）系统并在三年后公布了第一个INN药名单。1990年左右有提案为单抗使用“-mab”，使用靶位与来源亚词干的现有系统在1991年到1993年发展完成。美国采用名（USAN）委员会与WHO协作后美国采用名下的抗体与INN系统下的名称基本相同。2009年前超过170种单抗按照词命名法命名。<ref name="WHO-INN" /><ref name="Drugs.com" />

WHO于2008年10月召集工作组修改单抗命名法，以响应同年4月第46届国际非专利药品名商讨会上提出的问题。WHO于2009年11月加入了新的靶位亚词干。<ref name="WHO-INN" />2010年春INN录入了第一个以新系统命名的抗体。<ref name="Olaratumab" />

2017年4月第64届国际非专利药品名商讨会上WHO决定不再使用来源亚词干，自此新抗体命名不需带有此部分。<ref name="WHO_2017" />修改过的命名法在同年五月公布。<ref name="WHO 2017 Revised nomenclature" />旧命名法无法区分生产抗体药物方法的细节区别，也无法体现生产方法的复杂性；上述原因在内的因素导致INN放弃来源亚词干。<ref name="PARREN_2017" /><ref name="WHO 2017 Revised nomenclature" />
==例子==
=== 二十世纪八十年代 ===
* [[莫罗单抗-CD3|莫罗单抗-CD3]]于1986年获准临床运用，早于任何命名法。莫罗单抗-CD3是针对CD3的小鼠单克隆抗体的缩写（''mur''ine ''mon''oclonal ''a''nti''b''ody targeting ''CD3''）。<ref name="Mutschler" />

=== 2009年前 ===
* [[阿达木单抗|阿达木单抗]]针对[[肿瘤坏死因子-α|肿瘤坏死因子-α]]。其名称可拆分为“ada-lim-u-mab”，是针对免疫系统的人类单抗。若该药于2009年至2017年命名，则为“ada-l<s>i</s>-u-mab”；若在2017年后命名则为“ ada-li-mab”。<ref name="Adalimumab" />
* {{link-en|阿昔单抗|abciximab}}常用于阻止[[血小板|血小板]]凝结。其名称可拆分为“ab-ci-xi-mab”，是针对心血管系统的嵌合单抗。该名称以2009年及2017年命名法仍然相同。<ref name="Abciximab" />
* [[曲妥珠单抗|曲妥珠单抗]]用于治疗[[乳腺癌|乳腺癌]]。其名称可拆分为“tras-tu-zu-mab”，是针对肿瘤的人源化单抗。<ref name="Trastuzumab" />
* {{link-en|培阿赛珠单抗|alacizumab pegol}}是以聚乙二醇修饰、针对循环系统的人源化单抗。<ref name="Alacizumab" />
* {{link-en|锝-99m平妥单抗|Technetium (99mTc) pintumomab|锝（<sup>99m</sup>Tc）平妥单抗}}<ref name="Pintumomab" />和{{link-en|锝-99m巯诺莫单抗|Technetium (99mTc) nofetumomab merpentan|锝（<sup>99m</sup>Tc）巯诺莫单抗}}是带有放射性同位素标记的单抗；巯代表默喷坦（merpentan），是[[锝-99m|锝-99m]]的螯合剂。<ref name="Merpentan" />
* {{link-en|rozrolimupab|rozrolimupab}}可拆分为“rozro-lim-u-pab”，是针对免疫系统的人类多克隆抗体。<ref name="Rozrolimupab">{{cite web |author1=USAN Council |title=Statement On A Nonproprietary Name Adopted By The Usan Council - Rozrolimupab |url=https://searchusan.ama-assn.org/usan/documentDownload?uri=/unstructured/binary/usan/rozrolimupab.pdf |publisher=American Medical Association |accessdate=2020-12-06 |ref=Rozrolimupab}}</ref>

=== 2009年至2017年 ===
* {{link-en|奥拉单抗|olaratumab}}是[[化疗|抗肿瘤药]]。其名称可拆分为“olara-t-u-mab”，是针对肿瘤的人单抗。<ref name="Olaratumab" />
* {{link-en|贝那利珠单抗|benralizumab}}用于治疗[[哮喘|哮喘]]。其名称可拆分为“ benra-li-zu-mab”，是针对免疫系统的人源化单抗。<ref name="Benralizumab" />

===2017年后===
* {{link-en|贝兰他单抗莫福汀|Belantamab mafodotin}}是[[化疗|抗肿瘤药]]。其名称可拆分为“ belan-ta-mab”，是针对肿瘤的单抗，带有与单甲基奥瑞他汀E化学上类似的细胞毒素。<ref>{{cite journal | vauthors=((World Health Organization)) | year=2018 | title=International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 80 | journal=WHO Drug Information | volume=32 | issue=3 | pages=431-2 | hdl=10665/330907 | hdl-access=free | id=License: CC BY-NC-SA 3.0 IGO }}</ref>

== 参见 ==
* {{link-en|治疗用单克隆抗体列表|List of therapeutic monoclonal antibodies}}
* {{link-en|单克隆抗体疗法|Monoclonal antibody therapy}}

== 来源 ==
{{Reflist|2|refs=
<ref name="Janeway">{{cite book | last1 = Janeway | first1 = CA, Jr. | last2 = Travers | first2 = P. | last3 = Walport | first3 = M. | last4 = Shlomchik | first4 = M. J. | authorlink = Charles Janeway | title = Immunobiology | edition = 5th | publisher = [[Garland_Publishing|Garland Publishing]] | year = 2001 | url = https://archive.org/details/immunobiology00char | isbn = 978-0-8153-3642-6 | url-access = registration }}</ref>
<ref name="AMA_2007">{{cite web |url=http://www.ama-assn.org/ama/pub/physician-resources/medical-science/united-states-adopted-names-council/naming-guidelines/naming-biologics/monoclonal-antibodies.page?|title=AMA (USAN) Monoclonal antibodies |accessdate=2007-08-15 |date=2007-08-07 |work=United States Adopted Names}}</ref>
<ref name="WHO_2009">{{cite web|url=https://www.who.int/medicines/services/inn/generalpoliciesmonoclonalantibodiesjan10.pdf|title=General policies for monoclonal antibodies|publisher=World Health Organization|accessdate=2010-06-08|date=2009-12-18|archive-date=2016-03-03|archive-url=https://web.archive.org/web/20160303205044/http://www.who.int/medicines/services/inn/generalpoliciesmonoclonalantibodiesjan10.pdf|dead-url=no}}</ref>

<ref name="WHO_2017">{{cite web|url=https://www.who.int/medicines/services/inn/64th_Executive_Summary.pdf|title=64th Consultation on International Nonproprietary Names for Pharmaceutical Substances, Geneva, 4-7 April 2017 Executive Summary|publisher=World Health Organization|accessdate=2017-08-22|date=2017-07-31}}</ref>
<ref name="WHO 2017 Revised nomenclature">{{cite web | url=https://www.who.int/medicines/services/inn/Revised_mAb_nomenclature_scheme.pdf | title=Revised monoclonal antibody (mAb) nomenclature scheme | location=Geneva | date=2017-05-26 | publisher=World Health Organization (WHO)}}</ref>
<ref name="StemBook_2009">{{cite web|url=https://www.who.int/medicines/services/inn/StemBook2009.pdf|title=The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances|pages=107–109, 168–169|year=2009|publisher=World Health Organization|accessdate=2010-02-22|archive-date=2018-09-20|archive-url=https://web.archive.org/web/20180920080555/http://www.who.int/medicines/services/inn/StemBook2009.pdf|dead-url=no}}</ref>
<ref name="WHO_1997">{{cite web |url=http://whqlibdoc.who.int/hq/1997/WHO_PHARM_S_NOM_1570.pdf |year=1997 |title=Guidelines on the Use of International Nonproprietary Names (INNs) for Pharmaceutical Substances |accessdate=2007-08-15 |pages=27–28 |website= |archive-date=2012-10-18 |archive-url=https://web.archive.org/web/20121018091359/http://whqlibdoc.who.int/hq/1997/WHO_PHARM_S_NOM_1570.pdf |dead-url=no }}</ref>
<ref name="Stern">{{Cite journal | last1 = Stern | first1 = M. | last2 = Herrmann | first2 =R.| title = Overview of monoclonal antibodies in cancer therapy: present and promise | journal = Critical Reviews in Oncology/Hematology | volume = 54 | issue = 1| pages = 11–29 | year = 2005 | doi = 10.1016/j.critrevonc.2004.10.011| pmid = 15780905}}</ref>
<ref name="Tabrizi">{{Cite journal | last1 = Tabrizi | first1 = M.| last2 = Tseng | first2 = C.| last3 = Roskos | first3 = L.| title = Elimination mechanisms of therapeutic monoclonal antibodies | journal = Drug Discovery Today | volume = 11 | issue = 1–2| pages = 81–88 | year = 2006 | pmid = 16478695| doi = 10.1016/S1359-6446(05)03638-X}}</ref>
<ref name="PARREN_2017">{{Cite journal | last1 = Parren | first1 = P.| last2 = Carter | first2 = P.J.| last3 = Pluckthun | first3 = A.| title = Changes to International Nonproprietary Names for antibody therapeutics 2017 and beyond: of mice, men and more | journal = mAbs | volume = 9 | issue = 6| pages = 898–906 | year = 2017 | pmid = 28621572| doi = 10.1080/19420862.2017.1341029 | pmc=5590622}}</ref>

<ref name="Lordick">{{Cite journal | doi = 10.1517/14712598.8.9.1407 | title = The evolving role of catumaxomab in gastric cancer | year = 2008 | last1 = Lordick | first1 = F.| last2 = Ott | first2 = K.| last3 = Weitz | first3 = J.| last4 = Jäger | first4 = D.| journal = Expert Opinion on Biological Therapy | volume = 8 | pages = 1407–15| pmid = 18694358 | issue = 9 }}</ref>
<ref name="Veronese">{{Cite journal | last1 = Veronese | first1 = F.| last2 = Pasut | first2 = G.| title = PEGylation, successful approach to drug delivery | journal = Drug Discovery Today | volume = 10 | issue = 21 | pages = 1451–1458 | year = 2005 | doi = 10.1016/S1359-6446(05)03575-0| pmid = 16243265}}</ref>
<ref name="Capromab">{{cite journal | publisher=World Health Organization | title=ATC/DDD Classification (final) | journal=WHO Drug Information | volume=15 | issue=2 | year=2001 | url=http://apps.who.int/medicinedocs/en/d/Js2288e/7.html | accessdate=2011-02-13 | archive-date=2011-07-22 | archive-url=https://web.archive.org/web/20110722013252/http://apps.who.int/medicinedocs/en/d/Js2288e/7.html | dead-url=no }}</ref>
<ref name="Glembatumumab">{{cite web|url=http://www.cancer.gov/drugdictionary/?CdrID=599456|title=Drug Dictionary: Glembatumumab vedotin|publisher=National Cancer Institute|date=2011-02-02|accessdate=2020-12-06|archive-date=2015-04-05|archive-url=https://web.archive.org/web/20150405093947/http://www.cancer.gov/drugdictionary?CdrID=599456|dead-url=no}}</ref>
<ref name="Merpentan">{{cite journal|url=http://apps.who.int/medicinedocs/pdf/s4894e/s4894e.pdf|title=International Nonproprietary Names (INN) for Pharmaceutical Substances: Names for radicals & groups comprehensive list|publisher=World Health Organization|journal=|volume=|issue=|year=2002|page=22|accessdate=2010-12-24|archive-date=2011-07-03|archive-url=https://web.archive.org/web/20110703193226/http://apps.who.int/medicinedocs/pdf/s4894e/s4894e.pdf|dead-url=no}}</ref>
<ref name="Drugs.com">{{cite web|url=https://www.drugs.com/inn.html|title=International Nonproprietary Names|publisher=Drugs.com|accessdate=2010-12-08}}</ref>
<ref name="Ranibizumab">{{cite journal | publisher=World Health Organization | title=International Nonproprietary Names for Pharmaceutical Substances (INN) | journal=WHO Drug Information | volume=18 | issue=1 | year=2004 | url=http://whqlibdoc.who.int/druginfo/18_1_2004_INN90.pdf | page=61 | accessdate=2010-06-08 | archive-date=2012-03-03 | archive-url=https://web.archive.org/web/20120303224033/http://whqlibdoc.who.int/druginfo/18_1_2004_INN90.pdf | dead-url=no }}</ref>
<ref name="Pexelizumab">{{cite journal | publisher=World Health Organization | title=International Nonproprietary Names for Pharmaceutical Substances (INN) | journal=WHO Drug Information | volume=15 | issue=2 | year=2001 | url=http://whqlibdoc.who.int/druginfo/DRUG_INFO_15_2_2001_INN-85.pdf | page=121 | accessdate=2010-06-08 | archive-date=2012-02-11 | archive-url=https://web.archive.org/web/20120211194429/http://whqlibdoc.who.int/druginfo/DRUG_INFO_15_2_2001_INN-85.pdf | dead-url=no }}</ref>
<ref name="Kitasato">{{cite journal | author = AGN | title = The Late Baron Shibasaburo Kitasato | url = https://archive.org/details/sim_canadian-medical-association-journal_1931-08_25_2/page/206 | journal = Canadian Medical Association Journal | year = 1931 | volume = 25 | issue = 2 | page = 206 | pmc=382621 | pmid=20318414}}</ref>
<ref name="Köhler">{{Cite journal | last1 = Köhler | first1 = G. | last2 = Milstein | first2 = C. | title = Continuous cultures of fused cells secreting antibody of predefined specificity. 1975 | journal = Journal of Immunology | volume = 174 | issue = 5 | pages = 2453–5 | year = 2005 | pmid = 15728446}}</ref>
<ref name="Lindenmann">{{Cite journal | last1 = Lindenmann | first1 = J. | title = Origin of the terms 'antibody' and 'antigen' | url = https://archive.org/details/sim_scandinavian-journal-of-immunology_1984-10_20_4/page/281 | journal = Scandinavian Journal of Immunology | volume = 19 | issue = 4 | pages = 281–5 | year = 1984 | pmid = 6374880| doi=10.1111/j.1365-3083.1984.tb00931.x}}</ref>
<ref name="Nobel-1901">{{cite web | url = http://nobelprize.org/nobel_prizes/medicine/laureates/1901/index.html | title = The Nobel Prize in Physiology or Medicine 1901 | accessdate = 2011-02-19 | publisher = Nobel Foundation | archive-date = 2018-12-26 | archive-url = https://web.archive.org/web/20181226101908/https://www.nobelprize.org/nobel_prizes/medicine/laureates/1901/index.html%0A%20 | dead-url = no }}</ref>
<ref name="Nobel-1984">{{cite web | url = http://nobelprize.org/nobel_prizes/medicine/laureates/1984/index.html | title = The Nobel Prize in Physiology or Medicine 1984 | accessdate = 2011-02-14 | publisher = Nobel Foundation | archive-date = 2018-12-26 | archive-url = https://web.archive.org/web/20181226105137/https://www.nobelprize.org/nobel_prizes/medicine/laureates/1984/index.html%0A%20 | dead-url = no }}</ref>
<ref name="WHO-INN">{{cite journal | title=International Nonproprietary Names | journal=WHO Drug Information | volume=23 | issue=3 | year=2009 | publisher=World Health Organization | pages=195–199 | url=https://www.who.int/medicines/publications/druginformation/issues/DrugInfo09_Vol23-3.pdf | accessdate=2010-12-08}}</ref>
<ref name="Olaratumab">{{cite journal|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/olaratumab.pdf|title=Statement on a Nonproprietary name adopted by the USAN Council: Olaratumab|publisher=American Medical Association|date=2010-03-08|accessdate=2010-06-08|journal=|archive-date=2016-08-15|archive-url=https://web.archive.org/web/20160815202425/http://www.ama-assn.org/ama1/pub/upload/mm/365/olaratumab.pdf|dead-url=no}}</ref>
<ref name="Benralizumab">{{cite journal|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/benralizumab.pdf|title=Statement on a Nonproprietary name adopted by the USAN Council: Benralizumab|publisher=American Medical Association|date=2010-03-08|accessdate=2010-06-08|journal=|archive-date=2016-08-15|archive-url=https://web.archive.org/web/20160815201934/http://www.ama-assn.org/ama1/pub/upload/mm/365/benralizumab.pdf|dead-url=no}}</ref>
<ref name="Adalimumab">{{Cite journal | last1 = Miyasaka | first1 = N.| title = Adalimumab for the treatment of rheumatoid arthritis | doi = 10.1586/1744666X.5.1.19 | journal = Expert Review of Clinical Immunology | volume = 5 | issue = 1 | pages = 19–22 | year = 2009 | pmid = 20476896| pmc = }}</ref>
<ref name="Golimumab">{{cite journal|url=http://whqlibdoc.who.int/druginfo/18_2_2004_INN91.pdf|title=International Nonproprietary Names for Pharmaceutical Substances (INN)|publisher=World Health Organization|journal=WHO Drug Information|volume=18|issue=2|year=2004|page=167|accessdate=2011-02-13|archive-date=2012-02-11|archive-url=https://web.archive.org/web/20120211194603/http://whqlibdoc.who.int/druginfo/18_2_2004_INN91.pdf|dead-url=no}}</ref>
<ref name="Abciximab">{{cite web|url=https://www.drugs.com/cdi/abciximab.html|title=Abciximab|work=Drugs.com|accessdate=2010-03-13|archive-date=2010-04-20|archive-url=https://web.archive.org/web/20100420014357/http://www.drugs.com/cdi/abciximab.html|dead-url=no}}</ref>
<ref name="Trastuzumab">{{cite web|url=https://www.drugs.com/cdi/trastuzumab.html|title=Trastuzumab|work=Drugs.com|accessdate=2010-06-08}}</ref>
<ref name="Alacizumab">{{cite journal|url=https://www.who.int/medicines/services/inn/INN_2008_list60.pdf|title=International Nonproprietary Names for Pharmaceutical Substances (INN)|publisher=World Health Organization|journal=WHO Drug Information|volume=22|issue=3|year=2008|page=221|accessdate=2010-06-08}}</ref>
<ref name="Pintumomab">{{cite journal|url=http://whqlibdoc.who.int/druginfo/INN_2002_list48.pdf|title=International Nonproprietary Names for Pharmaceutical Substances (INN)|publisher=World Health Organization|journal=WHO Drug Information|volume=16|issue=3|year=2002|page=264|accessdate=2010-06-08|archive-url=https://web.archive.org/web/20100121222637/http://whqlibdoc.who.int/druginfo/INN_2002_list48.pdf|archive-date=2010-01-21|dead-url=yes}}</ref>
<ref name="Mutschler">{{cite book|last1=Mutschler|first1=E.|last2=Geisslinger|first2=G.|last3=Kroemer|first3=H. K.|last4=Schäfer-Korting|first4=M.|title=Arzneimittelwirkungen|publisher=Wissenschaftliche Verlagsgesellschaft|location=Stuttgart|year=2001|edition=8|page=937|isbn=978-3-8047-1763-3|language=de}}</ref>
}}

[[Category:单克隆抗体类|命名法]]
[[Category:化学命名法|单克隆抗体]]